IP Library Granted Patent US 8,114,885
Granted Patent B2
US 8,114,885 · App. 11/830,608 · Granted Feb 14, 2012

Chemical compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,885
App. No.
11/830,608
Granted
Feb 14, 2012
Kind
B2
Abstract

Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Claims (22)

1. A compound of the formula:

2. A pharmaceutical composition comprising an effective amount of an active ingredient, and one or more pharmaceutically acceptable carriers, diluents or excipients, wherein said active ingredient is 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide monohydrochloride.

3. The pharmaceutical composition of claim 2 wherein the pharmaceutical composition is for oral administration.

4. The pharmaceutical composition of claim 2 , wherein said pharmaceutical composition comprises at least one diluent.

5. The pharmaceutical composition of claim 2 wherein said pharmaceutical composition comprising at least one excipient.

6. A pharmaceutical composition comprising:

(i) at least one diluent;

(ii) at least one disintegrant; and

(iii) 5-({4-[(2H-indazol-6yl)methyl)amino]pyrimidin-2yl}amino)-2-methylbenzenesulfonamide monohydrochloride.

7. The pharmaceutical composition of claim 6 further comprising at least one lubricant.

8. A method of treating a disorder in a human, wherein said disorder is selected from the group consisting of colon cancer and breast cancer, said method comprising administering to said human an effective amount of a compound according to claim 1 .

9. The method of claim 8 , further comprising administering to said human at least one additional anti-cancer therapy.

10. The method of claim 9 , wherein said additional anti-cancer therapy is a pharmaceutical active agent.

11. The method of claim 9 , wherein said additional anti-cancer therapy is selected from the group consisting of surgical therapy and radiotherapy.

12. A method of treating a disorder in a human, wherein said disorder is selected from the group consisting of colon cancer and breast cancer, said method comprising administering to said human a pharmaceutical composition according to claim 2 .

13. The method according to claim 12 wherein said disorder is breast cancer.

14. The method according to claim 12 wherein said disorder is colon cancer.

15. The method according to claim 8 wherein said disorder is breast cancer.

16. The method according to claim 8 wherein said disorder is colon cancer.

17. The pharmaceutical composition of claim 2 wherein the pharmaceutical composition is for oral administration, and wherein said pharmaceutical composition comprises at least one diluent.

18. The pharmaceutical composition of claim 2 wherein the pharmaceutical composition is for oral administration, wherein said pharmaceutical composition comprises at least one diluent, and wherein said pharmaceutical composition comprises at least one excipient.

19. The method of claim 15 , further comprising administering to said human at least one additional anti-cancer therapy.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: LEO OSPREY LIMITED
To: NOVARTIS AG
Reel/Frame 035771/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: GLAXOSMITHKLINE LLC
To: LEO OSPREY LIMITED
Reel/Frame 035762/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2014
From: BOLOOR, AMOGH; CHEUNG, MUI; HARRIS, PHILIP ANTHONY; HINKLE, KEVIN; STAFFORD, JEFFERY ALAN; VEAL, JAMES MARVIN
To: GLAXOSMITHKLINE LLC
Reel/Frame 032743/0260 →